Pharma News

Researchers in India and the US are testing a handy solar-powered device for early detection of oral cancer which could be integrated with mobile technology, enabling faster and accurate diagnostics in rural areas.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

A large number of research institutes as well as 80 private organisations are expected to participate in 'Arogya', a four-day fair on Indian systems of medicine, that begins in Varanasi in Uttar Pradesh.

In trying to understand how "female Viagra" will affect the brain of women users, researchers from the University of Wisconsin-Madison have found that when brain metabolism dipped in monkeys during tests, desire went up in them for popping "female Viagra".

Coconut milk has been proved to be the next best to breast milk and the Coconut Development Board (CDB) is set to promote it as a health drink and one to be used for cooking.

India's health system needs an urgent course correction across several key challenges, if the country is to achieve the government's vision of assuring health for all, says a paper in The Lancet.

Scientists have developed a device that electronically stimulates tear production, which will offer hope to sufferers of dry eye syndrome, one of the most common eye afflictions in the world.

-Two new reports say urgent action needed to build on new momentum

-The benefit cost ratio of investing in the scaling up nutrition programmes in India is 34 to 1

-India’s stunting “represents the largest loss of human potential in any country in human history

(BWI); NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.

Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.

[adsense:336x280:8701650588]